fda-approval
(3)
Six People in Auburn, Alabama Ran a Drug Company That Owned No Factory
They spent 20 years learning how the big pharmaceutical companies work, then built a lean generics shop in a college town - no factory, six people, and a strategy of copying the drugs everyone else found too hard.
The Cardiologist Who Wants to Grow Your Chicken Without the Chicken
A former heart doctor traded the cath lab for the bioreactor to grow chicken from cells. He made history, hit a $1 billion valuation, and then ran straight into state legislatures that would rather ban his product than taste it.
Phathom Pharmaceuticals
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company built around vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB) it licensed from Takeda in 2019 for the U.S., Europe and Canada. Its lead product, VOQUEZNA, won FDA approval in late 2023 - the first major innovation in U.S. GERD treatment in over 30 years - and is sold for non-erosive and erosive GERD plus H. pylori infection via its DUAL PAK and TRIPLE PAK regimens. The company reached $175.1 million in net revenue in 2025 and expects operating profitability in 2026.